In this article, we will discuss Belinostat (Dosage Overview). So, let’s get started.
Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
The recommended dosage of Belinostat is 1,000 mg/m² administered over 30 minutes by intravenous infusion once daily on Days 1-5 of a 21-day cycle. Cycles can be repeated every 21 days until disease progression or